Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10789578 | 0.84 | — | — | |
| SCHEMBL23174810 | 0.81 | IRAK4 (0.39) | CYP11B2EP300ARPGRCREBBP | |
| SCHEMBL19781860 | 0.81 | L3MBTL1 (0.47) | CYP19A1CYP11B2EP300ARPGR | |
| SCHEMBL18641909 | 0.78 | L3MBTL1 (0.38) | CYP19A1CYP11B2EP300NLRP3 | |
| SCHEMBL5796848 | 0.77 | CYP19A1 (0.39) | CYP19A1CYP11B2 | |
| SCHEMBL20530964 | 0.76 | — | — | |
| SCHEMBL21265473 | 0.76 | — | — | |
| SCHEMBL10784441 | 0.76 | — | — | |
| SCHEMBL7462189 | 0.76 | — | — | |
| SCHEMBL6249860 | 0.75 | IRAK4 (0.37) | EP300ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080556-B2 | 2-amino pyrimidine compounds as potent HSP-90 inhibitors | PFIZER INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2331544-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | Pfizer Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC | 2010-02-18 | — | — | US | disclosed |
| WO-2010018481-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | PFIZER INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041681-A1 | 2-AMINO PYRIMIDINE COMPOUNDS AS POTENT HSP-90 INHIBITORS | HSP90AB2P, HSP90AB1, HSP90AA1 | CYP19A1 4783/4885CYP11B2 4162/4885EP300 2134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.